Ascent Wealth Partners LLC boosted its position in shares of Masimo Co. (NASDAQ:MASI) by 8.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,246 shares of the medical equipment provider’s stock after acquiring an additional 1,037 shares during the period. Ascent Wealth Partners LLC’s holdings in Masimo were worth $1,831,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of MASI. Empowered Funds LLC acquired a new position in shares of Masimo in the 1st quarter valued at $1,572,000. Envestnet Asset Management Inc. increased its position in shares of Masimo by 15.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 32,899 shares of the medical equipment provider’s stock valued at $4,549,000 after buying an additional 4,394 shares in the last quarter. Piedmont Investment Advisors Inc. increased its position in shares of Masimo by 41.9% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 4,631 shares of the medical equipment provider’s stock valued at $497,000 after buying an additional 1,368 shares in the last quarter. Round Table Services LLC bought a new stake in shares of Masimo in the 1st quarter valued at $221,000. Finally, Fundsmith LLP bought a new stake in shares of Masimo in the 4th quarter valued at $51,470,000. Hedge funds and other institutional investors own 83.03% of the company’s stock.
A number of research firms recently commented on MASI. BidaskClub upgraded shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 14th. Needham & Company LLC reiterated a “buy” rating and set a $158.00 target price (up previously from $155.00) on shares of Masimo in a report on Tuesday, May 7th. Piper Jaffray Companies increased their target price on Masimo from $148.00 to $160.00 in a report on Friday, May 17th. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $153.00 target price for the company in a report on Wednesday, May 8th. Finally, Stifel Nicolaus increased their target price on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, May 17th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $154.25.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The company had revenue of $231.70 million during the quarter, compared to analysts’ expectations of $223.67 million. During the same quarter last year, the company earned $0.75 EPS. Masimo’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts predict that Masimo Co. will post 3.12 earnings per share for the current year.
In related news, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $145.00, for a total value of $1,450,000.00. Following the transaction, the director now directly owns 74,832 shares of the company’s stock, valued at $10,850,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Yongsam Lee sold 258 shares of Masimo stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $145.00, for a total transaction of $37,410.00. Following the completion of the transaction, the executive vice president now directly owns 73,736 shares in the company, valued at $10,691,720. The disclosure for this sale can be found here. Insiders have sold 76,242 shares of company stock valued at $10,846,053 over the last 90 days. Company insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Read More: What is a stock buyback?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.